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Abstract
Background and Objectives: Escherichia coli is the main cause of urinary tract infection regardless of age. If it harbors shiga toxin,
hemolytic uremic syndrome may occur. The aim of this study was to determine the incidence and prevalence of Shiga Toxin pro-
ducing E. coli (STEC), as a cause of urinary tract infection in Iran.
Methods: Major medical search engines, Iranian scientific search engines, and Iranian databases for thesis were searched for rel-
evant English or Persian keywords for urinary tract infection, shiga-toxin Escherichia coli, and hemolytic uremic syndrome in Iran,
which were published between 1985 and 2017. The study was followed by the PRISMA statement. Point prevalence and proportion
were calculated by random effect and I2 for heterogeneity and expressed as 95% confidence intervals. MedCalc version 15 and SPSS
IBM were used for statistical analysis.
Results: A total of six articles with 1,111 positive E. coli urine cultures met all the inclusion criteria and were eligible for the final anal-
ysis. All studies had a cross-sectional design. The qualities of two studies were poor with low to moderate risk of bias. Considering
32 samples reported as positive for STEC, the pooled prevalence for E. coli associated UTI was 3.46% (95% CI, 0.89 to 7.65, I2 = 86%). The
study was heterogeneous for publication bias.
Conclusions: This review indicated that STEC constituted some percentage of uropathogenic E. coli that required to be considered
during culture processing and longer clinical follow up of the patients for the occurrence of STEC-related morbidity.
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1. Background
Escherichia coli incorporated more than half of the un-
derlying cause of urinary tract infection (UTI) and break-
through UTIs (1). Escherichia coli carries shiga toxin and
might cause hemolytic uremic syndrome (HUS). It is char-
acterized as microangiopathic hemolytic anemia, throm-
bocytopenia, and a leading cause of acute kidney injury to
infants and children (2, 3). It is associated with high mor-
bidity and mortality, especially in underdeveloped coun-
tries. Furthermore, STEC is the most common cause of
post-infectious HUS. Patients with urinary tract infection
are at the risk of renal scar (4-6) and hypertension (7). Fur-
thermore, it is associated with urinary tract abnormali-
ties. For this reason, patients will be routinely screened (8)
for the existence of vesicoureteral reflux (9), urinary tract
obstruction, congenital abnormalities of kidney and uri-
nary tract, or voiding dysfunction (10, 11). Furthermore,
STEC-producing E. coli are rarely consider in hospitalized
patients with UTI (12). There are some studies that have in-
vestigated antibiotic resistance gene in this microorgan-
ism (12, 13). Nevertheless, there is no exact number of
the prevalence and incidence of STEC uropathogen in Iran.
However, patients with severe pyelonephritis would never
be assessed routinely for shiga toxin harboring. Labora-
tories are not aware of the importance of serotyping of
uropathogenic E. coli, so much the worse for STEC. The aim
of this review was to determine the extent to which STEC
was incorporated in E. coli as a uropathogen in Iran.
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2. Methods
2.1. Protocols and Registration
The preferred reporting items for systematic reviews
and meta-analysis (PRISMA guidelines) were used to run
this review (14). The protocol was registered on PROSPERO
(CRD42016033019) (15) and published (16).
2.2. Eligibility Criteria
The inclusion criteria were presence of urinary tract in-
fection investigated for STEC contamination in Iran, with
no limitation of age and language, and assessed between
1985 and 2017. The settings were laboratories, hospitals,
outpatient facilities, day-care centers, and military institu-
tions. Identification of STEC was by Sorbitol-MacConkey
(SMAC) agar, serotyping by any of the recognized tech-
niques, such as agglutination tests, and/or confirmed by
PCR for shiga toxins.
The researchers searched PubMed, Google
Scholar, OVID, SCOPUS, Web of Sciences, MagIran,
health.barakatkns.com, SID.ir, dociran, PDFiran,
Ganj.irandoc, and abstract books of congresses. Be-
sides checking for bibliography of included articles for
further references, the researchers made contact through
email with the authors if the data was missed in the report.
The following key words of Shiga toxigenic, enterohemor-
rhagic, verotoxin Escherichia coli, urinary tract infection,
hemolytic-uremic syndrome, E. coli O157:H7, and human
were used for the search and the identical Farsi key words
were used for Iranian databases.
Study selection and data collection process:
Three reviewers (AA, SN, RN) individually reviewed the
abstracts to designate the pertinent studies, in case of dis-
parity “NH” was a determiner. The STROBE statement was
used to assess the quality of studies as mentioned in the
protocol (15-17). Biography of study, language of study, cen-
ter of study, type of study, period of study, sample size, pa-
tient information (age, disease, and gender), technique of
STEC identification, type of STEC, and funding sources was
extracted. Hoy et al. (2012) bias appraisal checklist was
used to evaluate the articles (18).
2.3. Data Synthesis and Analysis
The prevalence was calculated from the number of
samples confirmed for STEC and total population of each
study. The incidence was calculated from the number of
STEC samples to the population of the city of study. The
statistics were taken from population and housing census
of the statistical center of Iran. Moreover, prevalence was
pooled using the random effects model with the reverse
variance technique of DerSimonian and Laird for between-
study variance estimation. Subsequently, confidence inter-
val as the normal approximation interval between the 95%
level was computed. Chi-squared tests and the I-squared
statistic to rate heterogeneity between the studies in effect
measures was used (I-squared value of > 50% denotes con-
siderable heterogeneity).
Provisional Search strategy for Pubmed:
(“urinary tract infections”[MeSH Terms] OR (“uri-
nary”[All Fields] AND “tract”[All Fields] AND “infec-
tions”[All Fields]) OR “urinary tract infections”[All Fields]
OR (“urinary”[All Fields] AND “tract”[All Fields] AND “infec-
tion”[All Fields]) OR “urinary tract infection”[All Fields])
OR “pyelonephritis”[MeSH Terms] OR “pyelonephritis”[All
Fields] OR “cystitis”[MeSH Terms] OR “cystitis”[All Fields]
AND shiga toxin[All Fields] OR “enterohaemorrhagic e
coli”[All Fields] OR “Escherichia coli o157”[MeSH Terms]
OR (“Escherichia”[All Fields] AND “coli”[All Fields] AND
“o157”[All Fields]) OR “Escherichia coli o157”[All Fields] OR
“enterohemorrhagic e coli”[All Fields] OR “enterohem-
orrhagic Escherichia coli”[MeSH Terms] OR (“enterohem-
orrhagic”[All Fields] AND “Escherichia”[All Fields] AND
“coli”[All Fields]) OR “enterohemorrhagic Escherichia
coli”[All Fields]
OR “enterotoxigenic Escherichia coli”[MeSH Terms]
OR (“enterotoxigenic”[All Fields] AND “Escherichia”[All
Fields] AND “coli”[All Fields]) OR “enterotoxigenic Es-
cherichia coli”[All Fields] OR “enterotoxigenic E coli”[All
Fields] OR (“haemolytic uraemic syndrome”[All Fields]
OR “hemolytic-uremic syndrome”[MeSH Terms] OR
(“hemolytic-uremic”[All Fields] AND “syndrome”[All
Fields]) OR “hemolytic-uremic syndrome”[All Fields] OR
(“hemolytic”[All Fields] AND “uremic”[All Fields] AND “syn-
drome”[All Fields]) OR “hemolytic uremic syndrome”[All
Fields]) OR (“shiga toxins”[MeSH Terms] OR (“shiga”[All
Fields] AND “toxins”[All Fields]) OR “shiga toxins”[All
Fields] OR “verocytotoxin”[All Fields]) AND (“Escherichia
coli”[MeSH Terms] OR (“Escherichia”[All Fields] AND
“coli”[All Fields]) OR “Escherichia coli”[All Fields] OR “e
coli”[All Fields])
AND (“iran”[MeSH Terms] OR “iran”[All Fields])
3. Results
At the preliminary search, 250 articles were detected;
16 studies were relevant (Figure 1). After reviewing the ab-
stract, a total of six potentially relevant articles containing
1,111 positive E. coli urine cultures were eligible for the final
analysis. Amongst them, 32 were positive for STEC. The de-
sign was cross sectional. Two studies had poor and the rest
had good/fair quality. One study evaluated mixed groups
of patients with either diarrhea or urinary tract infection
(19). Median duration of studies was 10 months (range 5 to
12 months) (Table 1). Detail of extracted data is shown in
Table 2.
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Records after duplicates removed    
(n = 1043)  
 
Records excluded   
(n = 793)  
Non relevant title / 
abstract  
 
 
Records excluded -no urine  
sample  
(n = 234)  
Food (39), Animal (52), Stool(71), 
Shigella (7), HUS (65)  
Records identified through 
database searching 
(n = 18303)
Additional records identified
through other sources
(n = 474)
Records screened
(n = 250)
Full-text articles assessed
for eligibility
(n = 16)
Studies included in 
qualitative synthesis 
(n = 6)
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 6)
Case reports (1), review 
articles (3), report of non-
Iranian subjects (1),
inadequate data (4), antibiotic
resistance (1)
Full-text articles excluded, 
with reasons
 (n = 10)
Figure 1. Flowchart for Selection of Manuscript STEC Uropathogene in Iran
Table 1. Summary of Studies About Urinary Tract Infection with Shiga Toxin Producing Escherichia coli in Iran
Study ID Age, y/Gender/Population E. coli STEC Date Duration
Study, mo
Setting,
Location
Identifying
Methods
Design Quality/Bias
Abbasi and
Tajbakhsh
(20)
1 - > 49; F: 51, M:
25/Symptomatic UTI
76 3 2014 12 Outpatient,
Shahrekord
PCR/LAT CS Good/Low
Mansouri et
al. (21)
UA/Symptomatic UTI 146 0 2010 -
2011
12 Outpatient,
Lorestan
PCR CS Poor/Low
Adeli et al.
(22)
Age-UA/F: 117, M: 29/UTI -
hospitalized
100 3 2001 -
2002
6 Hospital,
Lorestan
PCR CS Poor/Low
Nazemiet al.
(23)
UA/UTI 100 16 2010 -
2011
12 Laboratory,
Iran
PCR CS Good/Low
Navidinia et
al. (24)
1 - 12/Gender-UA/Suspected
to UTI
378 9 2008 -
2009
8 Hospital,
Tehran
PCR CS Good/Low
Aghaee (19) UA/Urine culture of patients
with diarrhea
311 1 1999 -
2000
5 Hospital,
Khoramabad
PCR CS Good/Low
Abbreviations: CS, cross sectional; LAT, latency-associated transcript; PCR, polymerase chain reaction; STEC, Shiga toxin-Escherichia coli.
The pooled prevalence of STEC in E. coli-associated UTI
was 3.46 (95% CI, 0.89 to 7.65; I2 = 93.6%; Figure 2). Virulence
factors were stx1 (n = 11), stx2 (n = 9), stx1, 2 (n = 6), stx1eaeA
(n = 1), and stx2 eaeA (n = 2).
Funnel plot (Figure 3) was asymmetric toward positive
axis in favor of publication bias and population hetero-
geneity and methodology design, thus the studies with
positive results were underestimated.
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Table 2. Summary of Data Extracted from Studies About Urinary Tract Infection with Shiga Toxin Producing Escherichia coli in Iran
Study ID Urine Positive for E. coli (n) Samples Positive for STEC
(n)
Stx1 (n) Stx2(n) Stx1,2(n) O157 (H7) (n)
Abbasi and Tajbakhsh (20) 76 3 2 Stx1eaeA (n = 1)
Mansouri et al. (21) 146 0
Adeli et al. (22) 100 3 1 Stx2eaeA (n = 2)
Nazemi, (23) 100 16 10 6 1 1 (7)
Navidinia et al. (24) 378 5 5
Aghaee (19)a 311 1 3
Abbreviations: n, number; STEC, Shiga toxin-Escherichia coli; Stx, shiga toxin.
aFarsi language.
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Study ID Total Sample Proportion (%) (95% CI) 
Adeli Z, 2013 100 3(0.62 -  8.52) 
Nazemi A, 2012 100 16(9.43 -  24.68) 
Mansouri F, 2014 146 0(0- 2.49) 
Abbasi k, 2015 76 3.95(0.82 -  11.10)  
Naeb-Agaie SM, 2006 100 1(0.02 - 5.45) 
Navidinia M, 2012 378 2.38 (1.1 -  4.47) 
Total (Fixed Effects) 900 2.93(1.93 -  4.25) 
Total (Random Effects) 900 3.46(0.89 - 7.65) 
Heterogeneity: Q = 36, DF = 5 (P < 0.0001), I2 = 86.14% 
Figure 2. STEC prevalence to positive urine cultures for E. coli between 1985 and 2017 in Iranian studies
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Figure 3. Funnel plot of studies for urine cultures positive for E. coli include a meta-
analysis with proportion plotted against standard error
4. Discussion
To the best of the author’s knowledge, this is the first
comprehensive report of uropathogen STEC in Iran. Data
from six cross–sectional studies with good to poor qual-
ity of acceptance and low to moderate of bias were used.
The prevalence of urinary STEC was approximately 3.46% in
E. coli positive UCs. There is little evidence regarding the
correlation between STEC uropathogen and HUS or Throm-
botic microangiopathy (TTP) (25-29).
Only one study performed a serotype for O157 (23). The
dominant virulence factors were stx1 and stx2. Surveying
of literature revealed the occurrence of non-O157 UTI asso-
ciated with HUS. The responsible serotypes were O113:H21,
O6:H1 (30), and O138:H- (31). In addition, in diarrhea nega-
tive HUS, other foci, such as urinary system, should be as-
sessed for STEC infection (32). It has been suggested that
UTI-associated HUS should be investigated for verotoxin-
producing E. coli (33). Because of high infectivity of this
pathogen even with low dose of this organism, the physi-
cian should be well informed to consider this possibility
and check VTEC in cases with aggressive manifestation of
urinary tract infection, diarrhea negative HUS, or TTP. The
central laboratories should be enlightened to be assem-
bled to investigate both O157 and non-O157 STEC in suspi-
4 Arch Pediatr Infect Dis. 2018; 6(3):e78816.
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cious victims.
Limitations: The heterogeneity of studies was one of
the major drawbacks. None of the studies followed the pa-
tients for occurrence of STEC complications, such as hem-
orrhagic colitis or hemolytic uremic syndrome, changes
in blood cells, or kidney function. None of the studies
reported the outcome of affected and non affected cases.
Small sample size was another limitation of the study.
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